Inhibition mechanism of SAHA in HDAC: a revisit.


SAHA (vorinostat, Merck) is a famous clinical drug for zinc-containing histone deacetylase (HDAC) targets against cancer and several other human disorders, whose inhibition mechanism (namely the protonation mechanism) upon binding to HDAC has been debated for more than ten years. It is very challenging to verify experimentally and is still controversial… (More)
DOI: 10.1039/c5cp05633k

1 Figure or Table


  • Presentations referencing similar topics